COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS

The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.

Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections

MEDICAL OR VETERINARY SCIENCE; HYGIENE

Medicinal preparations characterised by special physical form -Galenical forms characterised by the site of application-Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner 

PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 

Medicinal preparations containing organic active ingredients-Carbohydrates; Sugars; Derivatives thereof -Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters-Glucans-Cyclodextrins

Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics-Antivirals

SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates-Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin-Cyclodextrins; Derivatives thereof

Medicinal preparations containing organic active ingredients-Phosphorus compounds-Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols

Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient-the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates-the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit-inclusion complexes, e.g. clathrates, cavitates or fullerenes-using cyclodextrin 

Medicinal preparations characterised by special physical form -Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles -lyophilised ; , i.e. freeze-dried, solutions or dispersions 

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

General

Analytics

Cases

Patent Assignments

Citations